![A configuration of the eFlow platform, showing components that can be... | Download Scientific Diagram A configuration of the eFlow platform, showing components that can be... | Download Scientific Diagram](https://www.researchgate.net/publication/26238709/figure/fig6/AS:310027349970949@1450927688319/A-configuration-of-the-eFlow-platform-showing-components-that-can-be-customized-for-a.png)
A configuration of the eFlow platform, showing components that can be... | Download Scientific Diagram
![PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) | Markets Insider PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) | Markets Insider](https://mma.prnewswire.com/media/753414/Lamira_Nebulizer_System.jpg)
PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) | Markets Insider
![LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension) LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)](https://mma.prnewswire.com/media/1472397/eFlow_Partnering_eBase_Controller_Lamira.jpg?p=facebook)